

# Embase<sup>®</sup>

## Fact Sheet



### ANSWERS BASED ON COMPREHENSIVE, UP-TO-DATE INFORMATION

In the biomedical domain users are looking for answers based on comprehensive, up-to-date information. That's precisely what Embase delivers, thanks to a database of over 8,500 biomedical journals, including all the titles covered by MEDLINE<sup>®</sup>, and deep, comprehensive indexing.





# Embase®

## Fact Sheet

### What is it and why is it needed?

With over 31 million indexed records and more than 8,500 indexed peer-reviewed journals, Embase is a highly versatile, multipurpose and up-to-date database covering the most important international biomedical literature from 1947 to the present day. All articles are indexed in depth using the Elsevier Life Science thesaurus Emtree®, and the entire database is available on multiple platforms.

On the Elsevier platform, [www.embase.com](http://www.embase.com), users looking for drug, medical device and disease-related information, are provided with the intuitive search tools they need to find answers to their research questions.

---

### FEATURES

Embase coverage at a glance:

- Journal coverage back to 1947 (when Embase Classic is included)
- Over 31 million records, including 1.8 million records from Embase Classic and records from all MEDLINE titles
- Over 8,500 journals from over 90 countries, including all MEDLINE titles
- Over 2,900 currently indexed journals that are unique to Embase, i.e. are not available from MEDLINE
- Over 1.5 million records added annually, with on average more than 6,000 records each working day
- More than 2.1 million conference abstracts indexed from over 6,000 conferences (dating back to 2009)

---

### EMBASE INDEXING


- All records are indexed in depth with Emtree terms.
- Emtree includes over 71,000 preferred terms, half of which are drug and chemical terms: over three times as many as listed by MeSH.
- In addition, Emtree lists over 3,000 medical devices.
- All MeSH terms are mapped to Emtree and drug, disease and medical device terms are qualified by subheadings that define the context of use of each term.
- Five key drug subheadings and two disease subheadings (from 2009) and two device subheadings (from 2014) are further qualified to show the linked drug, disease or device terms.
- Additional index terms include drug and medical device trade names and manufacturer names, CAS registry numbers and molecular sequence numbers.

## EMBASE FUNCTIONALITY

- All records in Embase, including all MEDLINE content, are searchable with a single query; de-duplication by the user is not required.
- Users can choose Emtree or MeSH terminology to carry out searches.
- Emtree explosion searches retrieve records indexed with the same class, particularly for drugs, diseases and devices.
- Daily updates ensure the database is current.
- Provisionally indexing of “in process” and pre-publication (“articles in press”) records mean searches are as up-to-date as possible.
- Email alerts and RSS feeds can be run on any schedule as defined by the user.
- Search results can be refined using biomedical and bibliographic filters.
- Search results are linked to full text data (e.g., via OpenURL), subject to availability.
- Data exports are available in a variety of formats (including RIS).

## EMBASE SCOPE AND CONTENT

Embase has a broad biomedical scope, with in-depth coverage of pharmacology, pharmaceutical science and clinical research. Basic biomedical science, veterinary science and extensive allied health topics are also included.




**Figure 1** Coverage of core topics grouped into 19 super categories.

## SUMMARY

With a total content over 8,500 journal titles, Embase covers over 60 topic areas. 19 core pharmacology and clinical topics represent over 70% of Embase content, drawn from over 5,000 journal titles.

Over 30% of Embase journal titles are unique (i.e., not covered by MEDLINE). This Embase-unique content includes 30% of the core pharmacology and clinical topic journal titles.



## LEARN MORE

To request information or a product demonstration, please visit [elsevier.com/embase](http://elsevier.com/embase) or email us at [embase@elsevier.com](mailto:embase@elsevier.com).

Visit [www.elsevier.com/rd-solutions](http://www.elsevier.com/rd-solutions) or contact your nearest Elsevier office.

### ASIA AND AUSTRALIA

Tel: + 65 6349 0222

Email: [sginfo@elsevier.com](mailto:sginfo@elsevier.com)

### JAPAN

Tel: + 81 3 5561 5034

Email: [jpinfo@elsevier.com](mailto:jpinfo@elsevier.com)

### KOREA AND TAIWAN

Tel: +82 2 6714 3000

Email: [krinfo.corp@elsevier.com](mailto:krinfo.corp@elsevier.com)

### EUROPE, MIDDLE EAST AND AFRICA

Tel: +31 20 485 3767

Email: [nlinfo@elsevier.com](mailto:nlinfo@elsevier.com)

### NORTH AMERICA, CENTRAL AMERICA AND CANADA

Tel: +1 888 615 4500

Email: [usinfo@elsevier.com](mailto:usinfo@elsevier.com)

### SOUTH AMERICA

Tel: +55 21 3970 9300

Email: [brinfo@elsevier.com](mailto:brinfo@elsevier.com)